RE:lumino Therapeutics is an ophthalmology spin-off developing first-in-class bispecific antibodies for major retinal diseases. Lead asset NN4101 combines VEGF-trap technology with c-Kit inhibition to deliver superior efficacy and extended durability for DME and wet AMD, with potential across DR and RVO. The company also holds an option to in-license NN4103, a complement/c-Kit bispecific for Geographic Atrophy. Backed by strong preclinical data and an experienced team, RE:lumino is advancing toward IND-enabling studies and a Phase 1 readout in 2028. We are seeking meetings with venture investors and participation in our Series A financing.